Home ›
Gastric Cancer Trials ›
NCT06054906
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer
To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) in resectable locally advanced gastric cancer.
Trial Details
NCT ID NCT06054906
Phase PHASE2
Sponsor Huashan Hospital
Status RECRUITING
Cancer Type Gastric Cancer
Interventions sintilimab+metronomic POLF
Locations (sample) Shanghai, China|31.22222,121.45806
Key Eligibility Criteria
Signed written Informed Consent Form Male or female, age ≥ 18 years old Histologically confirmed gastric adenocarcinoma, diagnosed as locally progressive according to the AJCC 8th ed, cTNM diagnosis of cT3-4aN1-3M0 and … No prior systemic therapy such as surgery, radiotherapy, or immunotherapy for the disease at hand
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Gastric Cancer Trials on Trialify →